Short-term human movements play a major part in the transmission and control of COVID-19, within and between countries. Such movements are necessary to be included in mathematical models that aim to assist in understanding the transmission dynamics of COVID-19. A two-patch basic mathematical model for COVID-19 was developed and analyzed, incorporating short-term human mobility. Here, we modeled the human mobility that depended on its epidemiological status, by the Lagrangian approach. A sharp threshold for disease dynamics known as the reproduction number was computed. Particularly, we portrayed that when the disease threshold is less than unity, the disease dies out and the disease persists when the reproduction number is greater than unity. Optimal control theory was also applied to the proposed model, with the aim of investigating the cost-effectiveness strategy. The findings were further investigated through the usage of the results from the cost objective functional, the average cost-effectiveness ratio (ACER), and then the infection averted ratio (IAR).
Hepatitis C virus (HCV) infection remains highly prevalent among people who inject drugs (PWID), where treatment effectiveness is strongly influenced by adherence and behavioral relapse. In this study, we develop and analyze a deterministic compartmental model to examine the impact of treatment adherence, relapse, and risk-reduction behaviors on HCV transmission dynamics. The model incorporates key behavioral pathways, including treatment initiation, partial adherence, and relapse to high-risk behavior. Analytical results establish positivity and boundedness of solutions, and the basic reproduction number is derived using the next-generation matrix approach. We show that the disease-free equilibrium is globally asymptotically stable when the reproduction number is below unity, while uniform persistence and a globally stable endemic equilibrium occur when transmission exceeds this threshold. Numerical simulations and sensitivity analyses indicate that the probability of transmission per needle-sharing event and the number of sharing partners are dominant drivers of epidemic persistence. In contrast, treatment uptake and sustained adherence significantly reduce transmission. Relapse to drug misuse undermines treatment benefits by expanding the infectious pool. These findings underscore the importance of integrating antiviral therapy with behavioral support to achieve long-term HCV control among PWID.